The characterization of BC molecular subtypes has improved the disease management in last years; thus, this heterogeneous disease has been classified in three basic therapeutic groups according to the expression of the progesterone (PR) and/or estrogen (ER) receptors and the human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to breast cancer.